RESUMEN
Stat electroencephalograms (sEEG) recorded over a one year period were analyzed to determine the rate of seizure or status epilepticus (SE) detection and the best predictors based on: ordering physician, clinical indication for study, and clinical history. All consecutive sEEG reports done over a year period at our institution were retrospectively reviewed. The following data were evaluated: sEEG findings, clinical history, clinical indication for study, requesting physician, location of patient, and demographics. Univariate analysis followed by a multivariate regression model analysis was performed. Of the 3,471 inpatient EEGs performed during the review period, 778 (22.4%) were sEEGs. 3.5% (n = 27) nonconvulsive status epilepticus (NCSE), 0.4% (n = 3) convulsive status epilepticus (CSE), and 1.1% (n = 9) had discrete electrographic seizures giving a total yield of 5.0% (39/778) patients with seizures or SE. A multivariate logistic retrospective model looking at ordering physician, clinical indication, and clinical history found that only clinical indications (overt continuous seizures/movements and witnessed seizure without return to baseline) were significant in the overall model. In our tertiary care institution sample, the rate of detecting status epilepticus or seizures among sEEG is low compared to prior studies. The best clinical predictors of finding SE or discrete seizures were overt continuous seizures/movements or witnessed seizure without return to baseline.
Asunto(s)
Electroencefalografía/estadística & datos numéricos , Servicios Médicos de Urgencia/estadística & datos numéricos , Epilepsia/diagnóstico , Epilepsia/epidemiología , Derivación y Consulta/estadística & datos numéricos , Arizona/epidemiología , Femenino , Humanos , Masculino , PrevalenciaRESUMEN
BACKGROUND: Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a condition of presumed autoimmune etiology that can present with a variety of neuropsychiatric signs and symptoms. OBJECTIVE: To illustrate the clinical findings and treatment options of this underdiagnosed condition. METHOD: We present a case of a patient diagnosed with SREAT and review the available literature including management of psychiatric symptoms. RESULTS: Little has been reported about the psychiatric management of patients with SREAT. CONCLUSION: Psychiatrists practicing in the general hospital setting should be aware of this often unrecognized entity to ensure accurate diagnosis and timely treatment.
Asunto(s)
Enfermedad de Hashimoto/diagnóstico , Antipsicóticos/uso terapéutico , Biopsia , Diagnóstico Diferencial , Quimioterapia Combinada , Glucocorticoides/uso terapéutico , Enfermedad de Hashimoto/tratamiento farmacológico , Enfermedad de Hashimoto/etiología , Enfermedad de Hashimoto/psicología , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Piperazinas/uso terapéutico , Factores de Riesgo , Terminología como Asunto , Tiazoles/uso terapéuticoRESUMEN
The role of pharmacological and surgical management of epilepsy continues to expand, but these treatments are often associated with significant side effects and morbidity. As a result, many patients with epilepsy and their physicians alike have gained interest in the role of vitamins and other dietary supplements for seizure management. In this review, we examine the potential anticonvulsant and proconvulsant effects of commonly used dietary supplements, as well as their potential effects on cognition or behavior. Our review was conducted through a literature search focusing on clinical trials involving patients with epilepsy and their seizure response to dietary supplementation. We summarize findings from previous clinical studies and comment on practical considerations regarding dietary supplementation for patients with epilepsy.
Asunto(s)
Suplementos Dietéticos , Convulsiones/dietoterapia , Vitaminas/uso terapéutico , HumanosRESUMEN
BACKGROUND: No data exists on the breast and cervical cancer screening practices among Cambodian, Laotian, Thai, and Tongan women. In this article, we describe the efforts required to conduct a baseline survey among these non-English-speaking women using the participatory action research (PAR) approach. METHODS: We tailored small population sampling techniques to each of the populations in partnership with Community Health Outreach workers. RESULTS: A total of 1825 surveys were successfully conducted in 8 communities. CONCLUSION: PAR and the culturally based techniques used to conduct the survey proved successful in maintaining scientific rigor, developing true community-researcher partnership, and achieving over 99% participation.
Asunto(s)
Pueblo Asiatico/estadística & datos numéricos , Neoplasias de la Mama/etnología , Neoplasias de la Mama/prevención & control , Participación de la Comunidad , Investigación sobre Servicios de Salud , Nativos de Hawái y Otras Islas del Pacífico/estadística & datos numéricos , Neoplasias del Cuello Uterino/etnología , Neoplasias del Cuello Uterino/prevención & control , Adulto , Anciano , California/epidemiología , Planificación en Salud Comunitaria/organización & administración , Relaciones Comunidad-Institución , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Persona de Mediana Edad , Muestreo , Encuestas y Cuestionarios , TraducciónRESUMEN
During the last 25 years, numerous studies have been conducted to promote breast cancer and cervical cancer screening. Most of these studies focused on individual-level factors predicting screening, but we are unaware of any that directly examined community and ecological influences. The goal of this project, Promoting Access to Health for Pacific Islander and Southeast Asian Women (PATH for Women), was to increase community capacity for breast and cervical cancer screening and follow up in Los Angeles and Orange counties. We focused on Southeast Asian and Pacific Islander women because, although they have the lowest rates for cancer, compared to all other ethnic groups, relatively few programs have specifically targeted Asian-American and Pacific Islander (AAPI) women to promote and sustain screening practices. The PATH for Women project involved a partnership between 5 community-based organizations and 2 universities, and included 7 Asian-American and Pacific Islander communities: Cambodians, Chamorros, Laotians, Thais, Tongans, Samoans, and Vietnamese. In this paper, we share our experiences in developing a Geographic Information System (GIS)-mapping evaluation component that was used to explore availability and accessibility to culturally responsive breast and cervical cancer screening services for Southeast Asian and Pacific Islander women in all 7 communities. We describe the methods used to develop the maps, and present the preliminary findings that demonstrate significant geographic and language barriers to accessing healthcare providers, services for breast and cervical cancer screening, and follow up, in each of the communities. Finally, we discuss implications for programs designed to promote breast and cervical screening and policy education.
Asunto(s)
Asiático , Neoplasias de la Mama/etnología , Neoplasias de la Mama/prevención & control , Instituciones Oncológicas/provisión & distribución , Planificación en Salud Comunitaria/organización & administración , Accesibilidad a los Servicios de Salud , Programas Gente Sana , Nativos de Hawái y Otras Islas del Pacífico , Neoplasias del Cuello Uterino/etnología , Neoplasias del Cuello Uterino/prevención & control , Adulto , California , Áreas de Influencia de Salud , Barreras de Comunicación , Femenino , Sistemas de Información Geográfica , Humanos , Los Angeles , Tamizaje Masivo/estadística & datos numéricos , Multilingüismo , Servicio Social/estadística & datos numéricosRESUMEN
PURPOSE: No standard, universally accepted therapy exists for patients with adenocarcinoma of the endometrium with peritoneal dissemination. We report mature outcomes of selected patients with this uncommon pattern of spread treated with whole abdomen radiotherapy (RT). METHODS AND MATERIALS: A retrospective review was undertaken of all patients with a diagnosis of endometrial cancer referred to the Radiologic Associates of Sacramento Medical Group between January 1, 1988 and October 1, 1999. Eleven patients were identified who had surgically proven peritoneal dissemination (peritoneal seeding) treated with whole abdomen RT as the sole cytotoxic therapy after operative cytoreduction. Ten patients had International Federation of Obstetrics and Gynecology (1988) Stage IV disease at diagnosis, and one had peritoneal dissemination at the time of initial recurrence after hysterectomy for Stage I disease. RT was administered to the whole abdomen using 10-MV photons in fractions of 1.0 or 1.5 Gy. A cumulative dose of 30 Gy was given in all patients, with shielding used to reduce the dose to the liver and kidneys. Partial abdominal volumes (pelvis plus paraaortic nodes) received supplementary dose at 1.5-1.8 Gy/fraction to bring the cumulative dose within the limited volumes to 46.2-54 Gy. RESULTS: Four patients developed progressive cancer within 13 months of completion of whole abdomen RT. One additional patient died of hepatic venoocclusive disease (radiation hepatitis) 15 months after RT without evidence of cancer recurrence. Five patients were alive and clinically cancer free 55, 129, 131, 134, and 178 months after RT completion. One patient died of unrelated causes 79 months after treatment completion. CONCLUSION: Abdominal RT, in doses compatible with the acute and late tolerance of normal tissues, can eradicate small deposits of disseminated, intraperitoneal endometrial cancer. Currently, our patient selection criteria include limited peritoneal dissemination at diagnosis permitting complete surgical clearance (<1 mm residual) of visible and palpable disease, Grade 1 or 2 histologic features, lack of demonstrable extraabdominal metastasis, and absence of major medical contraindications.
Asunto(s)
Adenocarcinoma/radioterapia , Adenocarcinoma/secundario , Neoplasias Endometriales/radioterapia , Neoplasias Peritoneales/radioterapia , Neoplasias Peritoneales/secundario , Abdomen , Anciano , Anciano de 80 o más Años , Neoplasias Endometriales/patología , Femenino , Humanos , Persona de Mediana Edad , Radioterapia/métodos , Dosificación Radioterapéutica , Estudios RetrospectivosRESUMEN
PURPOSE: The goal of three-dimensional (3-D) conformal radiation is to increase the dose delivered to tumor while minimizing dose to surrounding normal brain. Previously it has been shown that even escalated doses of 70 to 80 Gy have failure patterns that are predominantly local. This article describes the failure patterns and survival seen with high-grade gliomas given 90 Gy using a 3-D conformal intensity-modulated radiation technique. PATIENTS AND METHODS: From April 1996 to April 1999, 34 patients with supratentorial high-grade gliomas were treated to 90 Gy. For those that recurred, failure patterns were defined in terms of percentage of recurrent tumor located within the high-dose region. Recurrences with more than 95% of their volume within the high-dose region were considered central; those with 80% to 95%, 20% to 80%, and less than 20% were considered in-field, marginal, and distant, respectively. RESULTS: The median age was 55 years, and median follow-up was 11.7 months. At time of analysis, 23 (67.6%) of 34 patients had developed radiographic evidence of recurrence. The patterns of failure were 18 (78%) of 23 central, three (13%) of 23 in-field, two (9%) of 23 marginal, and zero (0%) of 23 distant. The median survival was 11.7 months, with 1-year survival of 47.1% and 2-year survival of 12.9%. No significant treatment toxicities were observed. CONCLUSION: Despite dose escalation to 90 Gy, the predominant failure pattern in high-grade gliomas remains local. This suggests that close margins used in highly conformal treatments do not increase the risk of marginal or distant recurrences. Our results indicate that intensification of local radiotherapy with dose escalation is feasible and deserves further evaluation for high-grade gliomas.